Charles
Myers, MD
WITHOUT A RANDOMIZED CONTROLLED TRIAL SHOWING AN IMPROVEMENT IN
OVERALL SURVIVAL, RADICAL PROSTATECTOMY SHOULD NOT BE ACCEPTED AS
STANDARD TREATMENT FOR NEWLY DIAGNOSED MEN WITH PROSTATE CANCER,
ESPECIALLY FOR THOSE WITH A GLEASON SCORE OF 6 OR BELOW AND A PSA
UNDER 10 NG/ML. IT IS TOO DAMAGING FOR THE PATIENT AND TOO EXPENSIVE
FOR OUR HEALTH CARE SYSTEM TO BE ACCEPTED WHEN WE STILL LACK PROOF
OF ITS EFFECTIVENESS.
Charles E. Myers, MD
Director
American Institute Diseases of the Prostate
Earlysville, Virginia 22936
434-964-0212
www.prostateforum.com
Message
Board
To learn
more about Prostatitis Research
Today is : November 20, 2008
You
are visitor number:
Disclaimer